Multimodales Management des Ovarialkarzinoms:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | German |
| Veröffentlicht: |
Bremen [u.a.]
UNI-MED-Verl.
2006
|
| Ausgabe: | 1. Aufl. |
| Schriftenreihe: | UNI-MED science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | 172 S. Ill., graph. Darst. |
| ISBN: | 3895997420 9783895997426 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV017995158 | ||
| 003 | DE-604 | ||
| 005 | 20061121 | ||
| 007 | t | ||
| 008 | 040406s2006 gw ad|| |||| 00||| ger d | ||
| 016 | 7 | |a 970788363 |2 DE-101 | |
| 020 | |a 3895997420 |c Gb. : ca. EUR 44.80 |9 3-89599-742-0 | ||
| 020 | |a 9783895997426 |9 978-3-89599-742-6 | ||
| 035 | |a (OCoLC)76685244 | ||
| 035 | |a (DE-599)BVBBV017995158 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a ger | |
| 044 | |a gw |c DE | ||
| 049 | |a DE-355 |a DE-578 | ||
| 084 | |a XH 8415 |0 (DE-625)152957:13144 |2 rvk | ||
| 084 | |a WP 322 |2 nlm | ||
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Multimodales Management des Ovarialkarzinoms |c [Hrsg.: Jalid Sehouli ...] |
| 250 | |a 1. Aufl. | ||
| 264 | 1 | |a Bremen [u.a.] |b UNI-MED-Verl. |c 2006 | |
| 300 | |a 172 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 650 | 4 | |a Combined Modality Therapy | |
| 650 | 4 | |a Ovarian Neoplasms |x therapy | |
| 650 | 0 | 7 | |a Eierstockkrebs |0 (DE-588)4013746-6 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Eierstockkrebs |0 (DE-588)4013746-6 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Sehouli, Jalid |d 1968- |e Sonstige |0 (DE-588)120960060 |4 oth | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010779236&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-010779236 | ||
Datensatz im Suchindex
| _version_ | 1804130621764665344 |
|---|---|
| adam_text | Inhaltsverzeichnis
1.1. Nationale und internationale Daten...................................................... 14
1.2. Risikofaktoren...........................................................................14
1.2.1. Alter..........................................................................................14
1.2.2. Sozioökonomischer Status.....................................................................14
1.2.3. Ethnische Herkunft............................................................................14
Î.2.4.
1.2.5. Reproduktion.................................................................................15
1.2.6. Umweltfaktoren...............................................................................17
2. | Ä4S®l®§üe 2®
2.1. Das hereditäre Ovariaikarzinom..........................................................20
2.1.1. Molekulare Grundlagen.......................................................................21
2.1.2. Testung.......................................................................................22
2.1.3. Beratung......................................................................................22
2.1.4. Möglichkeiten der Prävention.................................................................23
2.1.4.1. Chemoprävention...................................................................................23
2.1.4.2. Lebensstil und Diät..................................................................................23
2.1.4.3. Prophylaktische Operationen........................................................................23
2.1.4.4. Früherkennung.....................................................................................24
3. |
3.1. FIGO-Klassifikation....................................................................... 27
3.2. Oberblick über die histologische Klassifikation der primären Ovarialtumoren..............28
3.3. Abgrenzung zum Borderlinetumor des Ovars (BOT).......................................31
3.3.1. Definition.....................................................................................31
3.3.2. Epidemiologie................................................................................31
3.3.3. Klinik.........................................................................................31
3.3.4. Therapie......................................................................................33
3.3.5. Nachsorge....................................................................................35
3.3.6. Schlussfolgerungen...........................................................................36
J5.
5.1. Klinische Untersuchung..................................................................41
5.2.
5.3. Sonographie.............................................■ ■ •.............................43
5.4. Weitere Untersuchungsrnethoden........................................................44
5.5. Endoskopische Untersuchungsverfahren.............................................___48
5.6. Differentiaidiagnosen......................-.................................... —..... 43
12 Inhaltsverzeichnis
І б. І
6.1.
6.2.
63.
6.4.
6.5. Allgemeinzustand.......................................................................58
6.6. Postoperativer Tumorrest................................................................ 58
6.7. Lymphknotenstatus___.................................................................. 59
6.8. Aszitesmenge........................................................................... 60
6.9. Steroidhormone........___....................................___..................... 60
6.10.
6.11. CD24.................................................................................... 61
6.12. Ploidie und DNA-Index...................................................................61
6.13. Zytokine
6.14. HER-2/neu............................................................................... 61
6.15. P53...................................................................................... 62
6.16. CA-125-Serumlevel...................................................................... 62
6.17. COX-2................................................................................... 62
6.18. VEGF.................................................................................... 62
17.
7.1. Operative Therapie des Ovarialkarzinoms.................................................66
7.1.1. Einleitung.....................................................................................66
7.1.2. Operation - die 1. Säule der Therapie...........................................................66
7.1.3. Primäroperation...............................................................................66
7.1.4. Rezidivoperation..............................................................................67
7.1.5. Operatives Management......................................................................68
7.1.6. Lymphonodektomie...........................................................................71
7.1.7. Multiviszeraloperation.........................................................................73
7.1.8. Intervalloperation.............................................................................75
7.1.9.
7.1.10. Schlussfolgerungen...........................................................................76
7.2. Operative Therapie des fortgeschrittenen Ovarialkarzinoms___...........................80
7.3. Zytostatische Therapie...................................................................85
7.3.1. First-Line-Therapie............................................................................85
7.3.1.1. Chemosensitivitäts-Assays...........................................................................86
7.3.1.2. Behandlung der Frühstadien (FIGO l/ll)...............................................................86
7.3.1.3. Behandlung der fortgeschrittenen Stadien (FIGO III/IV)...............................................87
7.3.2. Aktuelle Studienkonzepte.....................................................................89
7.3.3. Bedeutung der Studienteilnahme beim Ovarialkarzinom.......................................96
7.4. Intraperitoneale Therapie beim Ovarialkarzinom- was ist wirklich dran?___................99
Inhaltsverzeichnis 13
1
9.1. Zytostatische Therapien......................___...___................___........... 109
9.1.1. Frührezidiv
9.1.2. Spätrezidiv...................................................................................112
9.2. Hormontherapien .......___..___...___.............................................. 115
|
10.1. Resistenzrnodulatoren.......___..___.........___...___...___......................118
10.2. Überexprimierte Targets........___........___........................___............ 118
10.3. Targets gegen Oberflächenantigene .....___..___..___...___.................___... 119
10.4. Angiogeneseinhibitoren.............___...........................................___120
10.5. Sonstige Ansätze....................................................................... 123
1
11.1. Aszites................................................................................. 129
11.2. Pleurodese............................................................................. 134
11.3. Heus...................................................................................
11.4. Kurzdarrnsyndrom nach Rezidivoperationen beim Ovarialkarzinorn........___.......... 145
11.5.
|12.| Ldexm
12.1. Einleitung.............................................................................. 149
12.2. Definition.............................................................................. 149
12.3. Messinstrumente der Lebensqualität.....___...........................................150
) 13.)
13.1. Ziele der Nachsorge.................................................................... 160
13.2. Untersuchung.......................................................................... 160
13.3. Psychologische Aspekte der Nachsorge...........................___.................. 161
13.4.
13.5. Bildgebende Verfahren................................................................. 168
13.6.
13.7. Therapienebenwirkungen..................___........................................168
13.8. Unkonventionelle Krebstherapien........___...........................................169
| |
|
| any_adam_object | 1 |
| author_GND | (DE-588)120960060 |
| building | Verbundindex |
| bvnumber | BV017995158 |
| classification_rvk | XH 8415 |
| ctrlnum | (OCoLC)76685244 (DE-599)BVBBV017995158 |
| discipline | Medizin |
| edition | 1. Aufl. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01536nam a2200421 c 4500</leader><controlfield tag="001">BV017995158</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20061121 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">040406s2006 gw ad|| |||| 00||| ger d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">970788363</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3895997420</subfield><subfield code="c">Gb. : ca. EUR 44.80</subfield><subfield code="9">3-89599-742-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783895997426</subfield><subfield code="9">978-3-89599-742-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)76685244</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV017995158</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 8415</subfield><subfield code="0">(DE-625)152957:13144</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WP 322</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Multimodales Management des Ovarialkarzinoms</subfield><subfield code="c">[Hrsg.: Jalid Sehouli ...]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. Aufl.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen [u.a.]</subfield><subfield code="b">UNI-MED-Verl.</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">172 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Combined Modality Therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ovarian Neoplasms</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Eierstockkrebs</subfield><subfield code="0">(DE-588)4013746-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Eierstockkrebs</subfield><subfield code="0">(DE-588)4013746-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sehouli, Jalid</subfield><subfield code="d">1968-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)120960060</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010779236&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-010779236</subfield></datafield></record></collection> |
| id | DE-604.BV017995158 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T19:23:57Z |
| institution | BVB |
| isbn | 3895997420 9783895997426 |
| language | German |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-010779236 |
| oclc_num | 76685244 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-578 |
| owner_facet | DE-355 DE-BY-UBR DE-578 |
| physical | 172 S. Ill., graph. Darst. |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | UNI-MED-Verl. |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Multimodales Management des Ovarialkarzinoms [Hrsg.: Jalid Sehouli ...] 1. Aufl. Bremen [u.a.] UNI-MED-Verl. 2006 172 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier UNI-MED science Combined Modality Therapy Ovarian Neoplasms therapy Eierstockkrebs (DE-588)4013746-6 gnd rswk-swf Eierstockkrebs (DE-588)4013746-6 s DE-604 Sehouli, Jalid 1968- Sonstige (DE-588)120960060 oth Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010779236&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Multimodales Management des Ovarialkarzinoms Combined Modality Therapy Ovarian Neoplasms therapy Eierstockkrebs (DE-588)4013746-6 gnd |
| subject_GND | (DE-588)4013746-6 |
| title | Multimodales Management des Ovarialkarzinoms |
| title_auth | Multimodales Management des Ovarialkarzinoms |
| title_exact_search | Multimodales Management des Ovarialkarzinoms |
| title_full | Multimodales Management des Ovarialkarzinoms [Hrsg.: Jalid Sehouli ...] |
| title_fullStr | Multimodales Management des Ovarialkarzinoms [Hrsg.: Jalid Sehouli ...] |
| title_full_unstemmed | Multimodales Management des Ovarialkarzinoms [Hrsg.: Jalid Sehouli ...] |
| title_short | Multimodales Management des Ovarialkarzinoms |
| title_sort | multimodales management des ovarialkarzinoms |
| topic | Combined Modality Therapy Ovarian Neoplasms therapy Eierstockkrebs (DE-588)4013746-6 gnd |
| topic_facet | Combined Modality Therapy Ovarian Neoplasms therapy Eierstockkrebs |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010779236&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT sehoulijalid multimodalesmanagementdesovarialkarzinoms |